We designed this workshop to bring together scientists across disciplines involved in early development to learn and apply smart drug design concepts. The ultimate goal is to demonstrate how every design decision has the potential to influence patient outcomes.
SOMERSET, N.J. (PRWEB) February 28, 2019
The Catalent Applied Drug Delivery Institute today announced that it is to hold a one-day symposium entitled “Smart Drug Development and Design” on Tuesday, March 12 at Northeastern University, Boston.
The symposium will be chaired by Cornell Stamoran, Ph.D., Co-Chair of the Catalent Applied Drug Delivery Institute, and will feature scientific experts from leading pharmaceutical companies and Rebecca Carrier, Ph.D., Professor and Associate Chair for Research, Chemical Engineering at Northeastern University.
The event will explore the key considerations for transitioning a molecule from discovery to clinic, including API and formulation development, pharmacokinetics, quality, and CMC requirements. The event will also include a discussion of patient-focused design principles and will give attendees the opportunity to apply what they have learned in a highly interactive audience participation session, as well as including ample time for networking.
“Through our interactions with leading innovators, we consistently hear that companies do not have all of the development resources needed, or cannot effectively share knowledge between departments. We designed this workshop to bring together scientists across disciplines involved in early development to learn and apply smart drug design concepts. The ultimate goal is to demonstrate how every design decision has the potential to influence patient outcomes,” commented Dr. Stamoran.
Established in 2012, the Catalent Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies to improve patient outcomes.
Registration and full details of the agenda can be found here.
About the Catalent Applied Drug Delivery Institute
The Catalent Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.
For more details on the Catalent Institute, visit http://www.drugdeliveryinstitute.com and follow the Catalent Institute on Twitter: @DrugDeliveryIns
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.
More products. Better treatments. Reliably supplied.™